



FINANCIAL TEAR SHEET

Corporate Profile

Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its two Pernix sales forces and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.

Primary IR

Contact

Bob Yedid
LifeSci Advisors
Phone: 646-597-6989
Fax: 516-428-8577
E-mail:
Bob@lifesciadvisors.com

Stock Information

PTX.O (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$2.52
Change (%)	▲ 0.06 (2.44%)
Volume	89,069
52 Week Low	\$2.00
Market Cap	\$29,919,350
Rolling EPS	-7.51
PE Ratio	0
Shares Outstanding	11,872,758

Data as of 03/16/18 4:00 p.m. ET



Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Press Releases & Upcoming Events

March 8, 2018 - 4:01 p.m.

Pernix Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

February 22, 2018 - 4:05 p.m.

Pernix Therapeutics to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Thursday, March 8

February 16, 2018 - 4:01 p.m.

Pernix Therapeutics Announces Launch of Authorized Generic Version of Treximet® by Company's Subsidiary, Macoven Pharmaceuticals

There are currently no events scheduled.

SEC Filings

Filing Date	Form
03/16/18	4
03/16/18	4
03/16/18	4
03/16/18	4

Corporate Governance

John Sedor	Chairman of the Board and CEO
Kenneth R. Piña	Senior Vice President, Chief Legal & Compliance Officer and Corporate Secretary
George P. Jones	Vice President of Sales and Marketing
Angus Smith	Vice President, Business Development & Strategic Planning